(Q27679553)

English

Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View

scientific article

In more languages

Statements

scholarly article

0 references

Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View (English)

0 references

0 references

0 references

object named as

Shi Hu

1

0 references

8

object named as

Weizhu Qian

0 references

4

object named as

Dapeng Zhang

0 references

11

object named as

Yajun Guo

0 references

3

object named as

Huaizu Guo

0 references

2

object named as

Shuaiyi Liang

0 references

6

object named as

Xiaoze Wang

0 references

7

object named as

Weili Yang

0 references

12

object named as

Zhiyong Lou

0 references

author name string

Hui Li

5

0 references

Sheng Hou

9

0 references

Hao Wang

10

0 references

language of work or name

0 references

publication date

20 September 2013

0 references

Journal of Biological Chemistry

0 references

288

0 references

38

0 references

27059-67

0 references

Structural Basis for Treating Tumor Necrosis Factor (TNF )-associated Diseases with the Therapeutic Antibody Infliximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779706

20 March 2017

Solution of the structure of the TNF-TNFR2 complex

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779706

20 March 2017

Crystal structure of TNFα complexed with a poxvirus MHC-related TNF binding protein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779706

20 March 2017

Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779706

20 March 2017

Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779706

20 March 2017

Likelihood-enhanced fast translation functions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779706

20 March 2017

Coot: model-building tools for molecular graphics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779706

20 March 2017

The CCP4 suite: programs for protein crystallography

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779706

20 March 2017

PHENIX: building new software for automated crystallographic structure determination

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779706

20 March 2017

https://api.crossref.org/works/10.1074%2FJBC.M113.491530

21 January 2018

Solvent content of protein crystals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779706

20 March 2017

Standard conformations for the canonical structures of immunoglobulins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779706

20 March 2017

Signalling pathways of the TNF superfamily: a double-edged sword

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779706

7 April 2017

Safety and efficacy of the tumor necrosis factor antagonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779706

29 September 2017

Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779706

29 September 2017

Engineering fully human monoclonal antibodies from murine variable regions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779706

29 September 2017

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779706

29 September 2017

The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779706

29 September 2017

Anti-TNF antibodies: lessons from the past, roadmap for the future

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779706

29 September 2017

Anti-TNF-alpha therapies: the next generation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779706

29 September 2017

Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779706

29 September 2017

TNF alpha and the TNF receptor superfamily: structure-function relationship(s).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779706

29 September 2017

Structure-activity studies of human tumour necrosis factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779706

29 September 2017

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide D

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779706

2 June 2018

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M113.491530

21 January 2018

Infliximab for Crohn's disease: the first 500 patients followed up through 2009.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M113.491530

21 January 2018

PROCHECK: a program to check the stereochemical quality of protein structures

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M113.491530

21 January 2018

Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M113.491530

21 January 2018

Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M113.491530

21 January 2018

The TNF superfamily in 2009: new pathways, new indications, and new drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/23943614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23943614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

What next after infliximab?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23943614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23943614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Letter: are infliximab and adalimumab similar for Crohn's disease in clinical practice?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23943614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1074/JBC.M113.491530

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27679553&oldid=1746131996"